CLINICAL TRIALS PROFILE FOR HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00515021 ↗ | Diurnal Variation of Plasminogen Activator Inhibitor-1 | Completed | National Center for Research Resources (NCRR) | Phase 4 | 2007-04-01 | To determine if nighttime administration of an aldosterone antagonist would effectively lower peak plasma Plasminogen Activator Inhibitor-1 (PAI-1) levels more effectively than morning administration. |
| NCT00515021 ↗ | Diurnal Variation of Plasminogen Activator Inhibitor-1 | Completed | Vanderbilt University Medical Center | Phase 4 | 2007-04-01 | To determine if nighttime administration of an aldosterone antagonist would effectively lower peak plasma Plasminogen Activator Inhibitor-1 (PAI-1) levels more effectively than morning administration. |
| NCT00648011 ↗ | Food Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accuretic™ Tablets 20 mg/25 mg | Completed | Mylan Pharmaceuticals | Phase 1 | 2003-08-01 | The objective of this study was to investigate the bioequivalence of Mylan's quinapril HCl and hydrochlorothiazide 20 mg/25 mg tablets to Parke-Davis' Accuretic™ 20mg/ 25 mg tablets following a single, oral 20/25 mg (1 x 20/25 mg) dose administration under fed conditions. |
| NCT00649441 ↗ | Fasting Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accuretic™ Tablets 20 mg/25 mg | Completed | Mylan Pharmaceuticals | Phase 1 | 2003-08-01 | The objective of this study was to investigate the bioequivalence of Mylan's quinapril HCl and hydrochlorothiazide 20 mg/25 mg tablets to Parke-Davis' Accuretic™ 20 mg/25 mg tablets following a single, oral 20 mg/25 mg (1 x 20 mg/25 mg) dose administered under fasting conditions. |
| NCT00651287 ↗ | A Study to Evaluate the Efficacy and Safety of Quinapril or Quinapril Plus Hydrochlorothiazide in Patients With Mild to Moderate Hypertension | Completed | Pfizer | Phase 4 | 2002-12-01 | The purpose of this study is to determine the response rate for the therapeutic goal (diastolic blood pressure (BP) less than 90 mmHg and systolic BP less than 140 mmHg) at Week 6 for quinapril 20 mg and at Week 12 for quinapril 20 mg, quinapril 40 mg, and quinapril 20 mg plus hydrochlorothiazide 12.5 mg; and to determine the mean decrease in diastolic and systolic BP measurements and the change in heart rate at Week 6 and Week 12 compared with baseline. |
| NCT00872235 ↗ | Bioequivalence Study of Quinapril Hydrochloride 20 mg and Hydrochlorothiazide 25 mg Tablets Under Fed Conditions | Completed | Ranbaxy Laboratories Limited | N/A | 2005-06-01 | This open-label, balanced, randomized, two-treatment, four-period, two-sequence, single dose, crossover fully replicated study was conducted on fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets of OHM Laboratories Inc. (division of Ranbaxy Laboratories Limited) and Accuretic 20-25 mg tablets of Parke-Davis (division of Pfizer Inc.) in healthy, adult, human, male, subjects under fed conditions. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE
Condition Name
Clinical Trial Locations for HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE
Trials by Country
Clinical Trial Progress for HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE
Sponsor Name
